Ralimetinib
 Ralimetinib structural formula | |
| Clinical data | |
|---|---|
| Other names | LY2228820 |
| Routes of administration | PO |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C24H29FN6 |
| Molar mass | 420.536 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ralimetinib (LY2228820) is a small molecule experimental cancer drug in development by Eli Lilly. Although originally thought to be a p38 mitogen-activated protein kinase (MAPK) inhibitor,[1] it has since been reported that it acts instead as an epidermal growth factor receptor (EGFR) inhibitor.[2]
A phase II trial for treatment of ovarian cancer has completed.[3][4]
References
[edit]- ^ Patnaik A, Haluska P, Tolcher AW, Erlichman C, Papadopoulos KP, Lensing JL, et al. (March 2016). "A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer". Clinical Cancer Research. 22 (5): 1095–1102. doi:10.1158/1078-0432.CCR-15-1718. PMID 26581242.
- ^ Bhattacharjee D, Bakar J, Chitnis SP, Sausville EL, Ashtekar KD, Mendelson BE, et al. (October 2023). "Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor". Cell Chemical Biology. 30 (10): 1211–1222.e5. doi:10.1016/j.chembiol.2023.09.013. PMC 10715717. PMID 37827156. S2CID 263962827.
- ^ Clinical trial number NCT01663857 for "A Study LY2228820 for Recurrent Ovarian Cancer" at ClinicalTrials.gov
- ^ Vergote I, Heitz F, Buderath P, Powell M, Sehouli J, Lee CM, et al. (January 2020). "A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer". Gynecologic Oncology. 156 (1): 23–31. doi:10.1016/j.ygyno.2019.11.006. PMID 31791552.